Pharmacokinetic Evaluation and Dosing of Subcutaneous Testosterone Pellets

被引:31
作者
Pastuszak, Alexander W. [1 ]
Mittakanti, Harsha
Liu, Jocelene S. [2 ]
Gomez, Lissette
Lipshultz, Larry I. [1 ]
Khera, Mohit [1 ]
机构
[1] Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA
[2] Northwestern Univ, Feinberg Sch Med, Dept Urol, Chicago, IL 60611 USA
来源
JOURNAL OF ANDROLOGY | 2012年 / 33卷 / 05期
关键词
Testosterone replacement; testosterone implant; hypogonadism; HYPOGONADAL MEN; BODY-COMPOSITION; OLDER MEN; REPLACEMENT; SAFETY; PHARMACODYNAMICS; RECOMMENDATIONS; DEFICIENCY; EFFICACY; IMPLANTS;
D O I
10.2164/jandrol.111.016295
中图分类号
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
摘要
Subcutaneous testosterone (T) pellets are a viable treatment modality for hypogonadism. Optimal dosing, frequency of reimplantation, and long-term safety of T pellets remain incompletely elucidated parameters. A retrospective review of 273 patients treated for hypogonadism using subcutaneous T pellets was performed. Serum total T (TT), free T (FT), and estradiol (E2) levels were analyzed as a function of time from implantation, number of pellets implanted (6-9 or 10-12), body mass index (BMI; <25 or >= 25 kg/m(2)), number of implantations (<= 4 rounds, 501 insertions), and preimplantation T levels (<300 or >= 300 ng/dL). T decay was determined using linear regression and TT levels immediately postimplantation and the time for TT levels to reach 300 ng/dL extrapolated for all variables. Mean patient age +/- SD was 56 +/- 12.6 years. Baseline TT level was 328 +/- 202 ng/dL, FT 9.49 +/- 27.8 pg/mL, and E2 25.1 +/- 17.3 pg/mL. Extrapolated TT and FT peaks were lower in men receiving 6 to 9 pellets than men receiving 10 to 12, although decay rates differed insignificantly. E2 levels rose significantly in men receiving 10 to 12 but not 6 to 9 pellets. Men with BMI >= 25 kg/m(2) attained lower TT peaks with slower decay than men with BMI <25 kg/m(2) receiving 10 to 12 pellets, although 300 ng/dL TT levels were reached at approximately 100 days in both groups. No differences were seen in decay rates for men with multiple implant rounds, and no differences in T peaks or decay rates were seen in men with preimplant T level <300 or >= 300 ng/dL. One patient developed erythrocytosis, and no prostate-specific antigen recurrences were observed in men with prostate cancer treated with T pellets. Men with BMI <25 kg/m(2) should receive fewer pellets, and reimplantation for all men should occur 100 to 120 days after prior implantation. Men receiving 10 to 12 pellets have higher E2 levels, potentially reflecting increased aromatization of T. Reimplantation and preimplantation TT levels do not affect pellet decay kinetics.
引用
收藏
页码:927 / 937
页数:11
相关论文
共 17 条
[1]   Prevalence of symptomatic androgen deficiency in men [J].
Araujo, Andre B. ;
Esche, Gretchen R. ;
Kupelian, Varant ;
O'Donnell, Amy B. ;
Travison, Thomas G. ;
Williams, Rachel E. ;
Clark, Richard V. ;
McKinlay, John B. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (11) :4241-4247
[2]   Issues in testosterone replacement in older men [J].
Bhasin, S ;
Bagatell, CJ ;
Bremner, WJ ;
Plymate, SR ;
Tenover, JL ;
Korenman, SG ;
Nieschlag, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (10) :3435-3448
[3]   Subcutaneous Testosterone Pellet Implant (Testopel®) Therapy for Men with Testosterone Deficiency Syndrome: A Single-Site Retrospective Safety Analysis [J].
Cavender, Richard K. ;
Fairall, Melissa .
JOURNAL OF SEXUAL MEDICINE, 2009, 6 (11) :3177-3192
[4]   Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men [J].
Dobs, AS ;
Meikle, AW ;
Arver, S ;
Sanders, SW ;
Caramelli, KE ;
Mazer, NA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (10) :3469-3478
[5]   PHARMACOKINETICS AND PHARMACODYNAMICS OF TESTOSTERONE PELLETS IN MAN [J].
HANDELSMAN, DJ ;
CONWAY, AJ ;
BOYLAN, LM .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 71 (01) :216-222
[6]   Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men [J].
Jockenhovel, F ;
Vogel, E ;
Kreutzer, M ;
Reinhardt, W ;
Lederbogen, S ;
Reinwein, D .
CLINICAL ENDOCRINOLOGY, 1996, 45 (01) :61-71
[7]   A Phase IV Prospective Evaluation of the Safety and Efficacy of Extended Release Testosterone Pellets for the Treatment of Male Hypogonadism [J].
Kaminetsky, Jed C. ;
Moclair, Betsy ;
Hemani, Micah ;
Sand, Matthew .
JOURNAL OF SEXUAL MEDICINE, 2011, 8 (04) :1186-1196
[8]   Testosterone release rate and duration of action of testosterone pellet implants [J].
Kelleher, S ;
Howe, C ;
Conway, AJ ;
Handelsman, DJ .
CLINICAL ENDOCRINOLOGY, 2004, 60 (04) :420-428
[9]   Medical progress - Risks of testosterone-replacement therapy and recommendations for monitoring [J].
Rhoden, EL ;
Morgentaler, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (05) :482-492
[10]   Testosterone and Growth Hormone Improve Body Composition and Muscle Performance in Older Men [J].
Sattler, Fred R. ;
Castaneda-Sceppa, Carmen ;
Binder, Ellen F. ;
Schroeder, E. Todd ;
Wang, Ying ;
Bhasin, Shalender ;
Kawakubo, Miwa ;
Stewart, Yolanda ;
Yarasheski, Kevin E. ;
Ulloor, Jagadish ;
Colletti, Patrick ;
Roubenoff, Ronenn ;
Azen, Stanley P. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (06) :1991-2001